MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 49, 2014, Pages 17606-17611

  Mohseni, Morassa ^a   Cidado, Justin ^a,c   Croessmann, Sarah ^a   Cravero, Karen ^a   Cimino Mathews, Ashley ^a   Wong, Hong Yuen ^a   Scharpf, Rob ^a   Zabransky, Daniel J ^a   Abukhdeir, Abde M ^a,d   Garay, Joseph P ^a   Wang, Grace M ^a   Beaver, Julia A ^a   Cochran, Rory L ^a   Blair, Brian G ^a   Rosen, D Marc ^a   Erlanger, Bracha ^a   Argani, Pedram ^a   Hurley, Paula J ^a   Lauring, Josh ^a   Park, Ben Ho ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c ASTRAZENECA   (United Kingdom)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; ER positive; MACROD2; Resistance; Tamoxifen

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; DNA LIGASE; HYDROLASE; MACROD2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ESTROGEN RESPONSIVE ELEMENT; GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROD2 GENE; OVERALL SURVIVAL; PHENOTYPE; PRIMARY TUMOR; PROTEIN EXPRESSION; RNA INTERFERENCE; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG RESISTANCE; FEMALE; GENE DELETION; GENE DOSAGE; GENETIC EPIGENESIS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROGNOSIS; TRANSGENE; TREATMENT OUTCOME; TUMOR CELL LINE;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESTROGENS; FEMALE; GENE DELETION; GENE DOSAGE; HUMANS; HYDROLASES; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSGENES; TREATMENT OUTCOME;

EID: 84917743746     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408650111     Document Type: Article

References (39)

1. Jordan VC (2004) Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 5(3):207-213.
2. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295 (5564):2465-2468.
3. Reiter R, Oh AS, Wellstein A, Riegel AT (2004) Impact of the nuclear receptor co-activator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 23(2):403-409.
4. Osborne CK, et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353-361.
5. Kurokawa H, et al. (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60(20):5887-5894.
6. Jin K, et al. (2012) The HOXB7 protein renders breast cancer cells resistant to ta-moxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 109(8): 2736-2741.
7. Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: Implications for breast cancer treatment. Cancer Res 72(13):3372-3380.
8. Bergamaschi A, Katzenellenbogen BS (2012) Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 31(1):39-47.
9. Iorns E, et al. (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13(2):91-104.
10. Abukhdeir AM, et al. (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 105(1):288-293.
11. Planas-Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17(7):4059-4069.
12. Jeselsohn R, et al. (2014) Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757-1767.
13. Toy W, et al. (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439-1445.
14. Robinson DR, et al. (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446-1451.
15. Merenbakh-Lamin K, et al. (2013) D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73(23): 6856-6864.
16. Li S, et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports 4(6):1116-1130.
17. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA (1997) An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57(7):1244-1249.
18. Feijs KL, Forst AH, Verheugd P, Lüscher B (2013) Macrodomain-containing proteins: Regulating new intracellular functions of mono(ADP-ribosyl)ation. Nat Rev Mol Cell Biol 14(7):443-451.
19. Chen D, et al. (2011) Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. J Biol Chem 286(15):13261-13271.
20. Rosenthal F, et al. (2013) Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases. Nat Struct Mol Biol 20(4):502-507.
21. Han WD, et al. (2007) Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor's transcriptional activity. Endocr Relat Cancer 14(3): 741-753.
22. Yang J, et al. (2009) The single-macro domain protein LRP16 is an essential cofactor of androgen receptor. Endocr Relat Cancer 16(1):139-153.
23. Rajaram M, et al. (2013) Two distinct categories of focal deletions in cancer genomes. PLoS ONE 8(6):e66264.
24. Cimino-Mathews A, et al. (2012) Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol 43(7):1003-1011.
25. Gerlinger M, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892.
26. Lin CY, et al. (2007) Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3(6):e87.
27. Torres-Arzayus MI, Zhao J, Bronson R, Brown M (2010) Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 70(10):4102-4111.
28. Levenson AS, Jordan VC (1997) MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 57(15):3071-3078.
29. Kyprianou N, English HF, Davidson NE, Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51(1):162-166.
30. Soule HD, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50(18):6075-6086.
31. Gustin JP, et al. (2009) Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106(8):2835-2840.
32. Abukhdeir AM, et al. (2006) Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat 99(1):23-33.
33. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1.
34. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486 (7403):346-352.
35. Bignell GR, et al. (2010) Signatures of mutation and selection in the cancer genome. Nature 463 (7283):893-898.
36. Bardelli A, et al. (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Disc 3(6):658-673.
37. Konishi H, et al. (2007) Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67(18): 8460-8467.
38. Konishi H, et al. (2007) A PCR-based high-throughput screen with multiround sample pooling: Application to somatic cell gene targeting. Nat Protoc 2(11):2865-2874.
39. Bachman KE, et al. (2004) p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther 3(2):221-225.